RAC 2.92% $1.94 race oncology ltd

Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-14

  1. 441 Posts.
    lightbulb Created with Sketch. 674
    “Impressive” and “Outstanding” are not terms thrown around without due evidence.

    Congratulations to the brave patients who made this result possible - and thoughts to the families of those who were simply too far gone to benefit. Their sacrifice will save many lives in time.

    I know many of us are exhausted from years of dreadful, disconnected market conditions. I hope this release is a reminder of how rare and powerful - and safe - this molecule is.

    In time, bisantrene will return to the market and you can all say you were a small part of that.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.